Primary immunodeficiency (PI) is a group of nearly 300 rare diseases wherein part of the immune system is missing or not functioning properly1,2. People with PI may be more susceptible to illness, take longer to recover and have recurring infections3, such as sinusitis, bronchitis, pneumonia, or gastrointestinal infections4. Physicians sometimes treat the infections while missing the underlying cause, leaving patients vulnerable to vital organ damage, physical disability, or even increased mortality risk5,6.
On average, it takes 12.4 years from symptom onset to a PI diagnosis7, meaning that many people with PI are sick on and off for more than a decade — potentially missing school, work, family and life. While an estimated 6 million people worldwide may be living with PI8, it is estimated that 70-90 percent of PI cases worldwide are undiagnosed9. Efforts at educating primary care physicians of the warning signs of Primary Immunodeficiency is an initiative that has been undertaken to increase in the number of patients diagnosed10. In addition, initiatives like newborn screening for severe combined immunodeficiency (SCID) are attempting to decrease the time to diagnosis for this disease in pediatric patients11. With proper treatment many people with PI can lead active, fulfilling lives by managing their condition.
We take pride in our long history of global industry-leading innovation and advancements in quality of care for individuals living with immune deficiency disorders, and believe in creating a world of new possibilities in immunology that make a meaningful difference in the lives of patients, caregivers, healthcare providers and the global healthcare community.
For more than eight decades, we have worked to unlock the potential of plasma to address a range of rare and chronic conditions12. Our scientists pioneered the modern-day approach to producing plasma-based treatments for therapeutic purposes back in the 1940s, when they discovered how to store plasma in a vacuum container for future use12. They also led efforts to refine fractionation.
Today, we are a recognized innovation leader, delivering unprecedented advances for the industry by offering plasma-based treatments for tens of thousands of patients in more than 50 countries and helping break down barriers to access13,14. As we continue to build our innovative pipeline, we are extending beyond plasma-derived treatments and utilizing novel technology platforms to meet evolving patient needs.
Through numerous state-of-the-art plasma collection facilities in the United States and Austria, we lead the industry in the collection of high-quality plasma from volunteer donors, that is then processed into life-saving plasma-derived therapies for patients. Today, as BioLife Plasma, we operate one of the largest and most sophisticated plasma collection, biologics production and plasma fractionation networks.
Through superior service, we maintain an unwavering commitment to the safety of our donors and the patients who receive plasma. Plasma donors are critical, as life-saving plasma can only be obtained from healthy adult donors, and cannot be produced in a laboratory or other artificial environment.
The following organizations may be a resource for information and support for patients, families, caregivers, healthcare providers, and researchers. Always speak with a physician or healthcare provider regarding any questions.